[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Luxembourg Institute of Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":362},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,68,104,129,156,184,212,235,260,281,311,334],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100644224","vocal-biomarkers-for-health-monitoring-an-open-longitudinal-hybrid-cohort-study-100644224",false,"NCT07665229","VOCAL BIOMARKERS FOR HEALTH MONITORING: AN OPEN LONGITUDINAL HYBRID COHORT STUDY","SONAR","Inclusion Criteria:\n\n* Adults ≥ 18 years.\n* Able to understand the study, provide informed consent and comply with study procedures (with reasonable accommodations as needed).\n* Speaks one of the study languages (FR\u002FEN\u002FDE\u002FPT).\n* Owns a smartphone compatible with the study app.\n\nExclusion Criteria:\n\n* \\- Acute clinical instability at inclusion (e.g., need for immediate medical care, severe respiratory distress, hospitalized patients not allowed to go out of their room) where study procedures could interfere with care.\n* Any other condition that, in the judgement of the Medical PI or delegated qualified staff, would place the participant at unreasonable risk or prevent meaningful participation, despite accommodations.",true,"ALL","18 Years",{"count":20,"type":21},3700,"ESTIMATED","OBSERVATIONAL","Voice could be considered a new vital sign in the future, being collected in routine care and complement other medical assessments.\n\nVocal biomarkers (VB) are voice characteristics that are specific to a disease or symptom. They can be utilized in clinical practice for remote disease monitoring, screening for diseases, or in clinical research as secondary endpoints to evaluate the efficacy of a treatment or intervention. They can also be used during enhanced consultations to screen for diseases or monitor the progression of a chronic disease, in services to identify at-risk patients, and at home to track patients' symptoms and general health status between consultations.\n\nDespite the potential of VB and many progresses, few have reached the stage of use in clinical routine.\n\nAt LIH, the Deep Digital Phenotyping research lab gained experience in the voice-related research field since 2019, with the implementation of methodological tools to collect and pre-process voice recordings, and with the development of vocal biomarker candidates in several therapeutic domains or symptoms (Type 2 diabetes, fatigue, COVID-19 and Long COVID, respiratory health, mental health, etc.) VB is an early-stage research topic; one needs to accelerate the development, validation and integration of vocal biomarkers for personalized medicine and innovative tools - both for clinical practice and remote patient monitoring.\n\nUntil now, VB candidates have been developed disease by disease, and there is a lack of data on the influence of concomitant diseases on voice signatures. Therefore, the next vital step to improve vocal biomarkers and assess their specificity is to compare them with both control groups, those without the disease, and those with other diseases.\n\nThe study is a cohort of adult people attending one of the hospitals in Luxembourg, either for an hospitalization, a consultation, or a simple visit, regardless of their health conditions. Study will be conducted in French, English, German, and Portuguese which are the most frequent languages in Luxembourg.\n\nStudy participants will be followed up over a 5 years period of time, with on-site study visits in study booths installed in the different hospitals in Luxembourg and at-home monitoring in-between visits, using a smartphone app to collect study data.\n\nDuring both study visits and at-home monitoring voice recordings will be collected together with health data. This will allow to understand how voice evolves with time in a given individual, and to identify VB specific to diseases like diabetes, or to symptoms common to several chronic diseases like fatigue or mental health problems.",[25],"Any Condition",[27,28,29,30],"Vocal biomarkers","Chronic disases","General health","Symptoms","NOT_YET_RECRUITING","2026-06-24",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":21},"2026-07",{"date":39,"type":21},"2031-05",{"name":41,"class":42},"Luxembourg Institute of Health","OTHER_GOV",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100631406","exploratory-clinical-evaluation-of-personalized-functional-profiling-in-gi-tumors-predicting-drug-response-in-crc-and-pdac-100631406","NCT07500259","Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC","COLOPan","Inclusion Criteria:\n\n* Signed informed consent form\n* ≥ 18 years of age\n* Willing and able to comply with the protocol for the duration of the study, including data and sample collection\n* Patient scheduled for surgery or biopsy (primary tumour or metastasis) PDAC\n\nExclusion Criteria:\n\n* Female patient, pregnant, planning a pregnancy or breastfeeding.\n* Known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.\n* Patient unable to understand and provide informed consent and has no family member representing him\u002Fher.\n* Patients with any other life-threatening illness, significant organ dysfunction or any clinically relevant conditions that, according to the hospital physician, could compromise the patient's safety.",{"count":51,"type":21},188,"The ColoPan study evaluates the scientific validity, reproducibility, and predictive performance of the Personalised Functional Profiling (PFP) platform in colorectal cancer and pancreatic ductal adenocarcinoma patients. It combines genomic sequencing with in vitro functional drug testing using patient-derived spheroids\u002Forganoids.",[54,55],"Colorectal Cancer","PDAC - Pancreatic Ductal Adenocarcinoma",[57,58,59],"Drug profiling","Precision medicine","clinical validation","2026-06-18",{"date":62,"type":35},"2026-06-23",{"date":64,"type":21},"2026-07-01",{"date":66,"type":21},"2034-11-01",{"name":41,"class":42},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100631405","advancing-diagnosis-and-treatment-of-pediatric-asthma-100631405","NCT07500246","Advancing Diagnosis and Treatment of Pediatric Asthma","Advancing Diagnosis and Treatment of Pediatric Asthma by Deep Immunophenotyping and Evaluation of Two Spacer Devices for Inhaled Corticosteroid Administration","Care4Asthma","Inclusion Criteria:\n\n* Patient aged between 5-16 years, male or female\n* Physician diagnosis of asthma requiring a controller treatment with ICS or ICS\u002FLong-acting beta-agonists (LABA) via MDI\n* Partly controlled or uncontrolled asthma based on GINA criteria and definitions\n* Informed consent signed by legally authorized representatives (LAR) and assent from young patient (only applicable for children ≥ 10 years)\n\nExclusion Criteria:\n\n* Patients with severe asthma exacerbation treated with systemic corticosteroids within the last 2 weeks or patients with active respiratory tract infection\n* Diagnosis of underlying chronic lung disease other than asthma (e.g., BPCO\u002Fcystic fibrosis etc.)\n* Severe asthma based on GINA definitions\n* Severe underlying disorders ((severe congenital heart disease, oncologic patients) (non-exhaustive list, left to the evaluation of the PI))\n* Immune deficiency or under immunosuppressive treatments\n* In receipt of immunotherapy (only for participants in Luxembourg donating samples for biomarker research)\n* Patients with neurological diseases \u002F impaired cognitive disorder\n* Siblings of patients already included in the study","5 Years","16 Years",{"count":79,"type":21},208,"INTERVENTIONAL",[82],"NA","Asthma is one of the most common chronic diseases in children, and treatment success often depends on proper inhaler use and consistent medication adherence. Exposure to allergens and pollutants can also impact treatment response and asthma control. Moreover, there is a growing need for non-invasive biomarkers to support better diagnosis and personalized care. The goal of this clinical trial is to investigate if a new digital inhaler can improve inhalation technique and treatment adherence in children aged 5 to 16 years old, with partly controlled or uncontrolled asthma requiring treatment with inhaled corticosteroids. The main questions it aims to answer are:\n\n* Does the use of a digital inhaler improve adherence to inhaled corticosteroids and asthma control in children?\n* Which biomarkers could support diagnosis and help predict treatment responses in children with asthma?\n* How do environmental factors influence asthma control and treatment outcomes?\n\nResearchers will compare adherence to inhaled corticosteroid therapy between children using a new digital inhaler (Whizz spacer) and those using a standard, non-digital inhaler (AeroChamber Plus® Flow-Vu®) to see if the digital inhaler improves treatment administration and asthma control. They will quantify inflammatory markers in biological samples from asthmatic children and children without respiratory disease, to find biomarkers linked to disease and treatment response.\n\nParticipants will:\n\n* Use the Whizz spacer or the AeroChamber Plus® Flow-Vu® during 12 weeks for corticosteroid inhalation, and complete daily a study diary to follow treatment administration.\n* Complete asthma control and quality of life questionnaires and have an evaluation of asthma control through GINA score at baseline, 6 and 12 weeks.\n* Undergo spirometry tests and FENO measurements at baseline and 12 weeks.\n* Give biological samples at baseline and 12 weeks.\n* Collect children's bedroom dust samples at baseline.\n* Wear a bracelet for 7 days at baseline and 12 weeks to monitor physical activity.",[85,86,87],"Asthma Childhood","Asthma","Inhalation Spacers",[86,89,90,91,92,93],"Child","Immunophenotyping","Environmental exposure","Inhalation spacers","Allergy and asthma","RECRUITING","2026-03-24",{"date":97,"type":35},"2026-03-30",{"date":99,"type":35},"2026-01-02",{"date":101,"type":21},"2027-08",{"name":41,"class":42},1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100606605","the--gal-syndrome---investigating-immune-reactions-to-tick-bites-100606605","NCT07177729","The α-gal Syndrome - Investigating Immune Reactions to Tick Bites","The α-gal Syndrome - Investigating Immune Reactions to Tick Bites Leading to Inflammation and Allergic Sensitization","ImmunoGal","Inclusion criteria:\n\n* Individuals aged ≥ 18 years, Male and Female.\n* Experience of a tick bite: the tick has been removed less than 48 hours ago, or the tick is still attached to the skin and can be removed on site by the study nurse.\n* Tick available for analysis.\n* Informed consent signed.\n\nExclusion criteria:\n\n* Individuals \\\u003C 18 years of age, Male or Female.\n* Individuals with an acute viral\u002Fbacterial inflammation.\n* Individuals with an immune deficiency or under immunosuppressive treatments.\n* Individuals in receipt with immunotherapy with omalizumab.\n* Individuals with neurological diseases \u002F impaired cognitive disorder.",{"count":113,"type":21},100,"Tick bites can transmit pathogens, but they can also induce a food allergy to mammalian meat. The goal of this clinical trial is to follow immune response and antibody build-up in individuals bitten by a tick. Participants are invited to enroll within 48 hours after the tick removal and donate some blood. The tick is also collected and analysed. Researchers will then try to answer the following questions:\n\n* Was the tick infected with parasites?\n* Did the participant make antibodies against tick proteins or tick-borne parasites?\n* Did the participant develop IgE antibodies against the alpha-Gal sugar? The alpha-Gal sugar is present on mammalian meat, and ticks can transmit the alpha-Gal sugar to the host during their blood meal. Humans recognize the alpha-Gal sugar as foreign and some individuals will build IgE antibodies in response. These IgE antibodies against alpha-Gal can lead to a food allergy to red meat, also known as alpha-Gal syndrome.\n\nResearchers will compare a group of participants that develop IgE against the alpha-Gal sugar with participants that will not. They want to find out if there are specific immune features that differentiate the 2 groups.\n\nParticipants will:\n\n* Enroll after a recent tick bite within 48 hours after tick removal: they will be asked to donate some blood and fill out a questionnaire.\n* Visit the clinic 4 to 6 weeks later for a follow-up sample and questionnaire.\n* Visit the clinic 3 months after the tick bite for allergy tests if they have been selected for this 3rd visit.",[116],"Alpha-Gal Syndrome",[118,119,120,121],"Tick-borne diseases","Tick bites","alpha-Gal syndrome","immuno-phenotyping",{"date":97,"type":35},{"date":124,"type":35},"2025-07-01",{"date":126,"type":21},"2027-02",{"name":41,"class":42},2,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":16,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":103},"100427639","identification-of-vocal-biomarkers-to-monitor-the-health-of-people-with-a-chronic-disease-100427639","NCT04848623","Identification of Vocal Biomarkers to Monitor the Health of People With a Chronic Disease","CoLive Voice","Inclusion Criteria:\n\n* Adolescents and adults \\> 15 years\n* With or without health conditions\n* From all countries\n\nExclusion Criteria:\n\n* Children \\\u003C 15 years","15 Years",{"count":138,"type":21},50000,"The CoLive Voice research project aims to identify vocal biomarkers of severe conditions and frequent health symptoms. The project is based on digital technologies and statistical algorithms. This is an international anonymous survey where vocal recordings are collected simultaneously with large validated clinical and epidemiological data, in the context of various chronic diseases or frequent health symptoms in the general population.",[141],"Chronic Disease",[143,144,145,146,147,148,149],"vocal biomarker","digital biomarker","digital health","artificial intelligence","telemonitoring","medical devices","precision health digital biomarker",{"date":97,"type":35},{"date":152,"type":35},"2021-06-26",{"date":154,"type":21},"2031-05-01",{"name":41,"class":42},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":164,"conditions":165,"keywords":170,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":103},"100614536","clinnova-ms-a-prospective-cohort-study-of-patients-with-multiple-sclerosis-a-trans-regional-digital-health-effort-unlocking-the-potential-of-artificial-intelligence-and-data-science-in-health-care-100614536","NCT07280871","Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care","Clinnova-MS","Inclusion Criteria:\n\n1. Signed informed consent form\n2. ≥ 18 years of age\n3. Willing and able to comply with the protocol for the duration of the study including data and samples collection as well as study visits and examinations.\n4. Diagnosed with MS according to the revised McDonald criteria 2017 or revised McDonald criteria 2024, all clinical forms inclusive (CIS, RRMS, SPMS, PPMS) AND early disease stages (\\\u003C 3 years), OR presenting at hospital for evaluation of a change in therapy (flare) OR transitioning phase to progressive disease as evaluated based on EDSS.\n\nExclusion Criteria:\n\n1. Diagnosis uncertain (no fulfilment of inclusion criteria)\n2. Any condition that could potentially hamper the compliance with the study protocol, including study procedures and study visits such as mental disability that makes it difficult or impossible to answer questionnaires.\n3. Not fluent in any of the following languages: French, English or German.\n4. Known pregnancy before the inclusion into the study",{"count":113,"type":21},"The Clinnova-Multiple Sclerosis (MS) study is part of the Clinnova program (NCT06526364; NCT06235684 and NCT05733702), which seeks to advance precision medicine and the digitalization of healthcare through high-quality, interoperable health data.\n\nThis program focuses on people with multiple sclerosis (MS) and aims to identify objective surrogate markers derived from clinical, epidemiological, imaging, and omics data that can predict disease activity, such as progression or relapses.\n\nBy combining data science and artificial intelligence, the project seeks to improve patient stratification, support personalized therapeutic decisions, and provide insights into the mechanisms underlying treatment response and disease progression.\n\nAlthough many therapies are available for MS, it remains challenging to determine the most appropriate strategy for each patient and to prevent long-term disability. Current treatments mainly target relapses and inflammation, with limited effects on chronic progression. Clinnova-MS will collect and analyze real-world and research data to better understand variability in disease activity and treatment outcomes, enabling more precise, evidence-based care within the standard of care. This study represents the first step toward the broader Clinnova objective: developing sustainable, personalized, and preventive healthcare for people living with MS.",[166,167,168,169],"Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Chronic Progressive","Clinically Isolated Syndrome","Primary Progressive Multiple Sclerosis",[171,172,173,174,175],"AI","Machine Learning","MS","phenotyping","personalised medicine","2025-12-31",{"date":178,"type":35},"2026-01-06",{"date":180,"type":21},"2026-06",{"date":182,"type":21},"2040-06",{"name":41,"class":42},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":16,"sex":17,"minAge":192,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":80,"phases":195,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":103},"100578811","healthyw860-pilot-100578811","NCT06816147","HealthyW8_60+ Pilot","Empowering Healthy Lifestyle Behavior Through Personalized Intervention Portfolios to Prevent and Control Obesity in the Elderly","HealthyW8","Inclusion Criteria:\n\nIndividuals aged 60 or older:\n\n* both males\u002Ffemales, general free-living population,\n* residing in Luxembourg,\n* having normal weight or being overweight, i.e., with a BMI between 18.5 ; 30 kg\u002Fm², which is considered a risk factor for developing obesity,\n* owning a smartphone.\n\nExclusion Criteria:\n\n* With known manifest chronic diseases that prohibits participation in the study (e.g., cancer, Parkinson's),\n* Persons with cognitive diseases (Alzheimer's) or those who are not able to lead an independent life,\n* Persons following a strict diet (on their own or advised by their physician),\n* Particular population groups, such as prisoners, the mentally disabled, or groups whose ability to give voluntary informed consent may be in question.","60 Years",{"count":194,"type":21},30,[82],"This pilot study will focus on men and women aged ≥60 years for a period of 3 months during which each participant will use the HLRS. The primary purpose is to study whether the HLRS, reflecting a multi-component intervention, is well accepted by the participant, has a decent adherence (i.e., user time of the app). In addition, investigators will study the feasibility of the design, i.e. whether the overall design is well suited to the participants, in order to improve their lifestyle, e.g., dietary habits and PA, among others. Secondary outcomes related to the feasibility approach include dietary habits, PA patterns, and selected plasma and urinary endpoints. This pilot study will be of longitudinal design without a control group. A later trial that is planned for the following year will focus further on biological endpoints and will be randomized. In this present pilot study, investigators aim to assess mainly the user-friendliness of the HLRS, and gather first evidence that the intervention can indeed produce healthier lifestyle patterns.\n\nThe study's primary objective is to determine whether the developed HLRS can be successfully applied to the target population (men and women aged ≥60 years) and whether they use it frequently during the study and are satisfied with the HLRS.\n\nSecondly, investigators will study whether the assessment of endpoints required for the later and separately planned ensuing long-term study can be well assessed within the study and if, despite the limited time of the intervention duration, the intervention will be able to preliminary improve specific markers related to the risk of obesity and associated comorbidities. This will entail anthropometric measures to assess changes in body mass and body fat in addition to the primary and secondary objectives.",[198],"Obesity Prevention",[200,201,202,203],"Obesity","BMI","overweight","life style recommender solution","2025-12-05",{"date":206,"type":35},"2025-12-12",{"date":208,"type":35},"2025-11-19",{"date":210,"type":21},"2026-12-31",{"name":41,"class":42},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":103},"100605013","development-of-voice-biomarkers-of-frequent-covid-19-and-long-covid-related-symptoms-based-on-data-from-users-of-the-long-covid-companion-app-100605013","NCT07156994","Development of Voice Biomarkers of Frequent COVID-19 and Long Covid-related Symptoms Based on Data From Users of the Long COVID Companion App","Unravelling Health and Frequent Symptoms and Voice Characteristics Evolution Over Time of Users of the Long COVID Companion Application to Develop Voice Biomarkers of Frequent Long Covid-related Symptoms","EVO-LC","Inclusion Criteria:\n\n* Adult (≥18 years old)\n* Male or female\n* People with persisting symptoms related to COVID-19 (With Long COVID diagnosis or not)\n* Adequate understanding of one of the study languages (English, French, German)\n* Electronically signed informed consent form\n\nExclusion Criteria:\n\n● No specific exclusion criteria",{"count":221,"type":21},300,"The LIH DDP research team focuses its research topics on vocal biomarkers and Long COVID, among others. Voice is indeed a promising tool to monitor health, as it contains many information on our health and is easy to collect.\n\nThe development of vocal biomarkers of Long COVID-related symptoms could improve the remote monitoring of the health status of people affected by this disease.\n\nThe LIH developed the Long COVID Companion (LCC) app in collaboration with the ApresJ20 Long COVID patient association in France to support patients in their daily lives. LCC app users will be invited to participate in this study to collect voice recordings at the same time as health-related data.\n\nThe objectives of this study are:\n\nPrimary objective: To develop vocal biomarker candidates for the main Long COVID symptoms (fatigue, brain fog, respiratory problems, sleep issues, stress, anxiety,..) in a population of people with Long COVID.\n\nSecondary objectives:\n\n* to assess the intra-individual longitudinal evolution of voice characteristics of people with LC\n* to assess app usability and acceptability in the long-term.",[224],"Long COVID",[224,27,226],"symptoms","2025-12-01",{"date":229,"type":35},"2025-12-08",{"date":231,"type":21},"2025-12-15",{"date":233,"type":21},"2028-09-30",{"name":41,"class":42},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":103},"100495630","clinnova-ibd-a-prospective-cohort-of-patients-with-inflammatory-bowel-disease-ibd-100495630","NCT05733702","Clinnova-IBD, a Prospective Cohort of Patients With Inflammatory Bowel Disease (IBD)","A Prospective Cohort Study of Patients With Inflammatory Bowel Disease: A Trans-Regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care","Clinnova-IBD","Inclusion Criteria:\n\n* ≥ 18 years old\n* Participants are willing and able to comply with the protocol including undergoing data and sample collection as well as study visits and examinations.\n* Signed informed consent form\n* Diagnosed with Inflammatory bowel disease, either Crohn's disease or ulcerative colitis, at least 3 months before the enrolment AND occurrence of a significant change in the treatment of the disease (either change of drug dosage OR change of medication within the same treatment class OR change of treatment class OR addition of a drug to a treatment regimen already ongoing). A change of drug dosage or frequency is considered significant if it fulfills the requirements in section 7.1 Note: Patients with ostomy or with short bowel syndrome can be included if they fulfill all the eligibility criteria\n\nExclusion Criteria:\n\n* Any condition that could potentially hamper the compliance with the study protocol, including study procedures and study visits (such as mental disability that makes it difficult or impossible to answer questionnaires)\n* Not fluent in any of the following languages: French, English or German\n* Known pregnancy",{"count":113,"type":21},"This study is part of the Clinnova program. This is a prospective cohort study including patients with IBD recruited at the time of a treatment change.\n\nAt least 800 participants (recruited in France, Germany and Luxembourg) will be enrolled, of which 100 participants are expected to be recruited in Luxembourg with the present study protocol.\n\nThe mission of Clinnova is to support the digitalization of healthcare and precision medicine by creating a data-enabling environment for accessing, sharing and analyzing interoperable, high-quality health data.\n\nThe main hypothesis is that treatment change decided by clinicians is predictable using objective surrogate markers derived from clinical, epidemiological, and omics data. Identifying these objective markers may facilitate future treatment decisions, provide new insights on the molecular causes for differential treatment response, pathogenesis and progression, and potential pointers for improved personalized therapeutic interventions.",[246],"Inflammatory Bowel Diseases",[248,249,250,251],"Artificial Intelligence","Personalized medicine","Treatment change","Phenotyping","2025-09-16",{"date":254,"type":35},"2025-09-22",{"date":256,"type":35},"2024-02-01",{"date":258,"type":21},"2029-11",{"name":41,"class":42},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":4},"100534196","clinnova-rd-a-prospective-cohort-study-of-patients-with-rheumatoid-diseases-100534196","NCT06235684","Clinnova-RD: A Prospective Cohort Study of Patients With Rheumatoid Diseases","Clinnova-RD: A Prospective Cohort Study of Patients With Rheumatoid Diseases: A Trans-Regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care","Clinnova-RD","Inclusion criteria:\n\n● Signed informed consent form\n\n* ≥ 18 years of age\n* Willing and able to comply with the protocol for the duration of the study including data and samples collection, study visits and examinations\n* Either newly diagnosed with a RD as defined in the diseases of interest below\\* requiring initiation of therapy OR treatment change , as per physician's discretion OR any increase in disease activity assessed by the rheumatologist to be relevant (e.g., flare(s) before the study visit) \\*For RA:\n* Participants fulfilling the 2010 ACR\u002FEULAR criteria for RA\n* Newly diagnosed RA in the last 2 years requiring initiation\u002Fchange of therapy OR any type of RA requiring treatment change\n\n  * For SLE:\n\n    * Participants fulfilling the 2019 ACR\u002FEULAR Classification Criteria of Systemic Lupus Erythematosus (SLE)\n  * For SSc:\n\n    • Participants fulfilling the 2013 ACR\u002FEULAR Classification Criteria for Systemic Sclerosis (Ssc)\n  * For ASSD:\n\n    * Participants fulfilling the 2010 Connor's criteria for ASSD\n\nExclusion criteria\n\n1. Any condition that could potentially hamper the compliance with the study protocol, including study procedures and study visits (such as mental disability that makes it difficult or impossible to answer questionnaires)\n2. Not fluent in any of the following languages: French, English or German\n3. Known pregnancy Note: If the participant is pregnant after inclusion and\u002For follow-up, this is not a reason for withdrawal.\n4. Participation in a prospective randomised interventional trial\n5. Decrease of disease activity\n6. Treatment change due to the unavailability of medication\n7. Treatment change due to safety reasons\n8. Disease-specific exclusion criteria:\n\nFor RA:\n\n• overlap of RA with any other rheumatic\u002Fimmunologic disease\n\nFor SLE:\n\n* overlap of SLE with any other rheumatic\u002Fimmunologic disease\n\nFor SSc:\n\n* overlap of SSc with any other rheumatic\u002Fimmunologic disease\n* other forms of SSc than diffuse cutaneous or limited cutaneous systemic sclerosis\n\nFor ASSD:\n\n* overlap of ASSD with any other rheumatic\u002Fimmunologic disease\n* other forms of myositis",{"count":113,"type":21},"This study is part of the Clinnova program. This is a prospective cohort study including patients with RD recruited at the time of a treatment change. At least 800 participants (recruited in France, Germany and Luxembourg) will be enrolled, of which 100 participants are expected to be recruited in Luxembourg with the present study protocol. The mission of Clinnova is to support the digitalization of healthcare and precision medicine by creating a data-enabling environment for accessing, sharing and analyzing interoperable, high-quality health data. The main hypothesis is that treatment change decided by clinicians is predictable using objective surrogate markers derived from clinical, epidemiological, and omics data. Identifying these objective markers may facilitate future treatment decisions, provide new insights on the molecular causes for differential treatment response, pathogenesis and progression, and potential pointers for improved personalized therapeutic interventions.",[271],"Rheumatoid Diseases",[248,249,250,251],"2025-09-02",{"date":275,"type":35},"2025-09-09",{"date":277,"type":21},"2026-04-01",{"date":279,"type":21},"2032-05-01",{"name":41,"class":42},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":80,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":103},"100545666","effect-of-shoe-cushioning-position-and-properties-on-running-related-injury-risk-100545666","NCT06384872","Effect of Shoe Cushioning Position and Properties on Running-related Injury Risk","Effect of Foam Properties and Cushioning Position of Running Shoes on Injury Risk in Leisure-time Runners: A Randomized Trial","RRI_Interv5","Inclusion Criteria:\n\n* Aged between 18 and 65 years\n* Willing to use the study shoes for each running training session, and only for running activities\n* Use a sports watch for training data recording\n* Accept to give access to running data via a Garmin Connect, Polar Flow or Suunto account, or accept to upload the GPX file (downloaded from another system) into the electronic system \"STRIDE\" for every running session\n* Signed electronic Informed Consent provided\n\nExclusion Criteria:\n\n* Women who are pregnant\n* Any contraindication to running training including cardiovascular\u002Frespiratory disease or running impeding injury\u002Fcondition at the time of initial inclusion;\n* A history of surgery to the lower limbs or the lower back within the previous 12 months or any degenerative conditions;\n* The use of orthopedic insoles for physical activity;\n* Any running injury (a physical pain or complaint related to running practice that causes the runner to interrupt or modify his\u002Fher training for at least one week) over the last month.\n\nNo limitation will be set regarding running experience, running level (performance), body mass or body mass index.","65 Years",{"count":291,"type":21},1068,[82],"The main purpose of this project is to investigate the influence of cushioning material at both the rear and the forepart of running shoes on musculoskeletal complaints in leisure-time runners. Therefore, the objectives are to investigate if\n\n1. \"Extra soft\" cushioning materials can reduce injury risk compared to stiffer materials;\n2. Cushioning under the forepart of the shoe also influences injury risk, independently of the cushioning at the rear part;\n3. Effects of cushioning material and position depend on the runner's body mass;\n4. Perception of cushioning is related to both shoe cushioning and injury risk;\n5. Other weight-bearing locomotion activities (i.e., number of steps per day besides running practice) represents an independent risk factor for running-related injury.\n\nThis study consists in a 6-month intervention trial during which leisure-time runners are required to follow their usual training schedule. Before the beginning of the study, the participants will receive a pair of running shoes. The three running shoe models will be exactly the same, except for their foam properties at the rear and forepart of the shoe, which will differ by 33 and 37%, respectively. The study shoes will be administered through random allocation. The participants will be required to use these shoes for all running sessions, and only for running activities.\n\nParticipants will first fill out a baseline questionnaire. During the intervention, data on running practice will be downloaded from sports watches via their respective app. Information on the use of the study shoes will be collected via a weekly questionnaire. Participants will be asked to fill out a weekly questionnaire on any musculoskeletal complaints experienced during the past 7 days. A questionnaire on the perception of cushioning will be filled in by the participants at three time points (after 5h of running, 25h of running, and at the end of follow-up).\n\nPrimary hypothesis:\n\n\\- Greater shock absorption properties at the rear part of running shoes are associated with a lower injury risk in recreational runners.\n\nSecondary hypothesis:\n\n* Greater shock absorption properties under the forepart of the shoe are also associated with lower injury risk in recreational runners.\n* Runners with low body mass experience a lower injury risk in shoes with greater shock absorption properties.\n* Greater perceived cushioning is related to lower injury risk.",[295],"Running-related Injury",[297,298,299,300,301,302],"Bodymass","Musculoskeletal","Prevention","Epidemiology","Footwear","Cushioning","2025-08-05",{"date":305,"type":35},"2025-08-06",{"date":307,"type":35},"2025-04-01",{"date":309,"type":21},"2026-06-30",{"name":41,"class":42},{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":333,"locationsCount":128},"100459765","earlier-diagnosis-and-better-treatment-mission-related-to-the-cohort-programme-100459765","NCT05266872","Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme","Biomaterial Collection for Neurodegenerative Disease Research (ND Collection)","LuxPARK","Inclusion Criteria:\n\n* Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism)\n* Subjects of all genders with a full capacity of consent\n* Subjects with a limited consent capacity if the legal guardian\u002Fauthorised representative is in agreement\n* Subjects of at least 18 years of age at the time of inclusion\n\nExclusion Criteria:\n\n* Refusal to sign the informed consent\n* Limited capacity of consent on the part of the donor, if there is no legally determined guardian\u002Fauthorised representative, or the latter is not present or does not agree with the inclusion\n* Active cancer\n* Pregnant women\n* Underage subjects of less than 18 years of age\n* Refusal to comply with mandatory sample collection\n* For invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings.",{"count":320,"type":21},1800,"The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.",[323],"Parkinson Disease",[325,326,327,328],"Parkinson's disease","longitudinal cohort","stratification","risk factors",{"date":305,"type":35},{"date":331,"type":35},"2014-12-19",{"date":176,"type":21},{"name":41,"class":42},{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":80,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":103},"100545678","physical-activity-promotion-in-osteoarthritis-patients-100545678","NCT06385028","Physical Activity Promotion in Osteoarthritis Patients","Personalized Physical Activity Promotion in Osteoarthritis Patients Using a Smartphone-based Solution","PIANISSIMO","Inclusion Criteria:\n\n* Osteoarthritis patients, living or working in Luxembourg\n* Signed informed consent form\n* Adequate understanding of one of the study languages (English, French, or German)\n* Stated willingness to comply with the study procedure consisting in completing the surveys and the digital physical activity intervention\n\nExclusion Criteria:\n\n* Rheumatoid arthritis",{"count":343,"type":21},150,[82],"The main purpose of this project is to promote physical activity in patients with osteoarthritis. More specifically, this study aims to test the acceptability of an app to promote physical activity in the target population, and consequently the feasibility of such an approach.\n\nA mobile phone application - namely PIANISSIMO - will be developed specifically for this project. It aims to spread knowledge on the benefits of physical activity and collect data on how this knowledge can induce behavior changes toward a more physically active lifestyle.\n\nThe intervention is delivered via the app, which will send daily notifications on physical activity and sedentary behavior, and ask the participants to set their weekly goal (i.e., daily steps). The app will also collect daily steps count and ask the participant to fill in questionnaire on pain once a week.",[347],"Osteoarthritis",[349,350,351,352,353],"physical activity promotion","daily steps","connected devices","knee","hip","2025-03-04",{"date":356,"type":35},"2025-03-07",{"date":358,"type":35},"2025-02-13",{"date":360,"type":21},"2026-07-31",{"name":41,"class":42},""]